Claims
- 1. An amine compound represented by the formula: ##STR464## or a pharmaceutically acceptable salt thereof, wherein R.sup.1 represents a phenyl, naphthyl, indanyl, thienyl or furyl group which may optionally be substituted by at least one substituent selected from the group consisting of halogen, hydroxyl, nitro, oxo, cyano, carboxyl, carbamoyl, mercapto, amino, C.sub.1-8 alkyl, C.sub.2-4 alkenyl, C.sub.1-4 alkoxy, C.sub.1-4 alkylthio, C.sub.1-4 alkylsulfinyl, C.sub.1-4 alkylsulfonyl, methylthiomethyl, ethylthiomethyl, methylthioethyl, methylsulfinylmethyl, ethylsulfinylmethyl, methylsulfinylethyl, methylsulfonylmethyl, ethylsulfonylmethyl, methylsulfonylethyl, hydroxy-C.sub.1-4 alkyl, C.sub.2-4 alkenyloxy, C.sub.1-4 alkoxy-C.sub.1-4 alkyl, 2-hydroxyethoxy, 3-hydroxypropoxy, halogeno-C.sub.1-4 alkyl, C.sub.1-4 alkylamino, di-C.sub.1-4 alkylamino, formyl, C.sub.2-5 alkanoyl, C.sub.5-8 cycloalkanecarbonyl, formyloxy-C.sub.1-4 alkyl, C.sub.2-5 alkanoyloxy-C.sub.1-4 alkyl, C.sub.5-8 cycloalkanecarbonyloxy-C.sub.1-4 alkyl, Benzoyloxy-C.sub.1-4 alkyl, toluoyloxy-C.sub.1-4 alkyl, 2-naphthoyloxy-C.sub.1-4 -alkyl, C.sub.3-7 cycloalkyl, phenyl, naphthyl, indanyl, benzyl, phenethyl, naphthylmethyl, ##STR465## wherein R.sup.6 and R.sup.7 which may be the same or different, represent hydrogen, C.sub.1-8 alkyl, C.sub.3-7 cycloalkyl, C.sub.2-4 alkenyl, benzyl, phenethyl, napthylmethyl, hydroxyl, halogeno-C.sub.1-4 alkyl, hydroxy-C.sub.1-4 alkyl, C.sub.1-4 alkoxy-C.sub.1-4 alkyl, amino-C.sub.1-4 alkyl, C.sub.1-4 alkylamino-C.sub.1-4 alkyl or di-C.sub.1-4 alkylamino-C.sub.1-4 alkyl, and A is a C.sub.1-4 alkylene, or R.sup.6 and R.sup.7 may be bonded together forming a nitrogen-containing saturated heterocycle thereby forming a ring selected from the group consisting of 1-pyrrolidinyl, piperidino, 3-hydroxy-1-pyrrolidinyl, 3-hydroxymethyl-1-pyrrolidinyl, 2-hydroxymethyl-1-pyrrolidinyl, 3-hydroxy-1-piperidinyl, 4-hydroxy-1-piperidinyl, 3-hydroxymethyl-1-piperidinyl, and 4-hydroxymethyl-1-piperidinyl; p is 0, 1, 2 or 3; X is an oxygen or sulfur atom; q is 2, 3 or 4; Z is oxygen, sulfur, NR.sup.4 wherein R.sup.4 is formyl, C.sub.2-5 alkanoyl, C.sub.5-8 cycloalkanecarbonyl, benzoyl, toluoyl, 2-naphthoyl, phenyl, naphthyl, indanyl, benzenesulfonyl, naphthalenesulfonyl, phenyloxy, naphthyloxy, formylamino, C.sub.2-5 alkanoylamino, C.sub.5-8 cycloalkanecarbonylamino, benzoylamino, toluoylamino, 2-naphthoylamino, each of which may optionally be substituted by at least one substituent selected from the group consisting of C.sub.1-8 alkyl, halogen-C.sub.1-4 alkyl, C.sub.1-4 alkoxy and halogen, or hydrogen, cyano, hydroxyl, nitro, C.sub.1-8 alkyl, C.sub.2-4 -alkenyl, C.sub.1-4 alkoxy, carbamoyl, sulfamoyl, C.sub.1-4 alkoxycarbonyl, C.sub.1-4 alkylsulfonyl, C.sub.1-4 alkoxycarbonylamino or carboxy-C.sub.1-4 alkylamino; Y is C.sub.1-4 alkylene; R.sup.2 is phenyl, indanyl, thienyl or furyl which may be optionally be substituted by at least one substituent selected from the group consisting of halogen, hydroxyl, nitro, amino, hydroxy-C.sub.1-4 alkyl, cyano, C.sub.1-8 alkyl, C.sub.1-4 alkoxy, C.sub.1-4 alkylthio, C.sub.1-4 alkylsulfinyl, C.sub.1-4 alkylsulfonyl, halogeno-C.sub.1-4 alkyl, di-C.sub.1-4 alkylamino, carbamoyl, or C.sub.2-5 alkanoyl, and R.sup.3 is a hydrogen or hydroxyl-protecting group selected from the group consisting of formyl, C.sub.2-5 alkanoyl, C.sub.5-8 cycloalkanecarbonyl, benzoyl, toluoyl, 2-naphthoyl, 2-phenoyl, 3-furoyl, nicotinoyl, 1,1-dimethylpropoxycarbonyl, t-butoxycarbonyl, isopropoxycarbonyl, 2,2,2-trichloroethoxycarbonyl, ethoxycarbonyl, 2,2,2-tribromoethoxycarbonyl, benzyloxycarbonyl, 4-nitrobenzyloxycarbonyl, 4-brmobenzyloxycarbonyl, 4-methoxybenzyloxycarbonyl, 3,4-dimethoxybenzyloxycarbonyl, 4-(phenylazo)benzyloxycarbonyl, 4-(4-methoxyphenylazo)benzyloxycarbonyl, monochloroacetyl, trifluoroacetyl, 2-furfuryloxycarbonyl, 1-adamantyloxycarbonyl, 8-quinolyloxycarbonyl, benzyl, diphenylmethyl, trityl, C.sub.1-8 alkyl, methoxymethyl, tetrahydrofuryl, tetrahydropyranyl, 2-nitrophenylthio, 2,4-dinitrophenylthio, trimethylsilyl and t-butyldimethylsilyl.
- 2. The amine compound of claim 1, wherein R.sup.1 is phenyl, indanyl, thienyl or furyl or one of these groups substituted by one of the substituents of claim 1.
- 3. The amine compound of claim 2, wherein the substituent on R.sup.1 is a member selected from the group consisting of halogen, hydroxyl, nitro, amino, hydroxy-C.sub.1-4 alkyl, cyano, C.sub.1-8 alkyl, C.sub.1-4 alkoxy, C.sub.1-4 alkylthio, C.sub.1-4 alkylsulfinyl, C.sub.1-4 alkylsulfonyl, halogeno-C.sub.1-4 alkyl, di-C.sub.1-4 alkylamino and carbamoyl.
- 4. The amine compound of claim 3, wherein Z is oxygen, C.sub.1-4 alkylsulfonylimino, benzenesulfonylimino, naphthalenesulfonylimino, cyanoimino or sulfamoylimino.
- 5. An amine compound of the formula: ##STR466## wherein R.sup.9 is a hydrogen or C.sub.1-8 alkyl group and R.sup.2, R.sup.3, R.sup.6, R.sup.7, A, p, q, X, Y and Z have the same meanings as defined in claim 1, or a pharmaceutically acceptable salt thereof.
- 6. An amine compound of the formula: ##STR467## wherein R.sup.9 is a hydrogen or C.sub.1-8 alkyl group, and R.sup.2, R.sup.3, R.sup.6, R.sup.7, A, p, q, X, Y and Z have the same meanings as defined in claim 1, or a pharmaceutically acceptable salt thereof.
- 7. An amine compound of the formula: ##STR468## wherein R.sup.2, R.sup.3, R.sup.6, R.sup.7, A, q, X, Y and Z have the same meanings as defined in claim 1, or a pharmaceutically acceptable salt thereof.
- 8. The amine compound as in any preceding claim, wherein Y is methylene.
- 9. The amine compound as in any one of claims 1 to 7, wherein R.sup.3 is hydrogen.
- 10. The amine compound as in any ne of claims 1 to 7, wherein R.sup.3 is one of the hydroxyl-protecting groups set forth in claim 1.
- 11. An amine compound represented by the formula: ##STR469## or a pharmaceutically acceptable salt thereof, wherein R.sup.1 represents a phenyl, naphthyl, indanyl, thienyl or furyl group which may optionally be substituted by at least one substituent selected from the group consisting of halogen, hydroxyl, nitro, oxo, cyano, carboxyl, carbamoyl, mercapto, amino, C.sub.1-8 alkyl, C.sub.2-4 alkenyl, C.sub.1-4 alkoxy, C.sub.1-4 alkylthio, C.sub.1-4 alkylsulfinyl, C.sub.1-4 alkylsulfonyl, methylthiomethyl, ethylthiomethyl, methylthioethyl, methylsulfinylmethyl, ethylsulfinylmethyl, methylsulfinylethyl, methylsulfonylmethyl, ethylsulfonylmethyl, methylsulfonylethyl, hydroxy-C.sub.1-4 alkyl, C.sub.2-4 alkenyloxy, C.sub.1-4 alkoxy-C.sub.1-4 alkyl, 2-hydroxyethoxy, 3-hydroxypropoxy, halogeno-C.sub.1-4 alkyl, C.sub.1-4 alkylamino, di-C.sub.1-4 alkylamino, formyl, C.sub.2-5 alkanoyl, C.sub.5-8 cycloalkanecarbonyl, formyloxy-C.sub.1-4 alkyl, C.sub.2-5 alkanoyloxy-C.sub.1-4 alkyl, C.sub.5-8 cycloalkanecarbonyloxy-C.sub.1-4 alkyl, benzoyloxy-C.sub.1-4 alkyl, toluoyloxy-C.sub.1-4 alkyl, 2-naphthoyloxy-C.sub.1-4 alkyl, C.sub.3-7 cycloalkyl, phenyl, naphthyl, indanyl, benzyl, phenethyl, naphthylmethyl, ##STR470## wherein R.sup.6 and R.sup.7, which may be the same or different, represent hydrogen, C.sub.1-8 alkyl, C.sub.3-7 cycloalkyl, C.sub.2-4 alkenyl, benzyl, phenethyl, naphthylmethyl, hydroxyl, halogeno-C.sub.1-4 alkyl, hydroxy-C.sub.1-4 alkyl, C.sub.1-4 alkoxy-C.sub.1-4 alkyl, amino-C.sub.1-4 alkyl, C.sub.1-4 alkylamino-C.sub.1-4 alkyl or di-C.sub.1-4 alkylamino-C.sub.1-4 alkyl, and A is a C.sub.1-4 alkylene; p is 0, 1, 2, 3; X is an oxygen or sulfur atom; q is 2, 3 or 4; Z is oxygen, sulfur or NR.sup.4 wherein R.sup.4 is formyl, C.sub.2-5 alkanoyl, C.sub.5-8 cycloalkanecarbonyl, benzoyl, toluoyl, 2-naphthoyl, phenyl, naphthyl, indanyl, benzenesulfonyl, naphthalenesulfonyl, phenyloxy, naphthyloxy, formyamino, C.sub.2-5 -alkanoylamino, C.sub.5-8 cycloalkanecarbonylamino, benzoylamino, toluoylamino, 2-naphthoylamino, each of which may optionally be substituted by at least one substituent selected from the group consisting of C.sub.1-8 alkyl, halogeno-C.sub.1-4 alkyl, C.sub.1-4 alkoxy and halogen, or hydrogen, cyano, hydroxyl, nitro, C.sub.1-8 alkyl, C.sub.2-4 alkenyl, C.sub.1-4 alkoxy, carbamoyl, sulfamoyl, C.sub.1-4 alkoxycarbonyl, C.sub.1-4 alkylsulfonyl, C.sub.1-4 alkoxycarbonylamino or carboxy-C.sub.1-4 alkylamino; Y is C.sub.1-4 alkylene; R.sup.2 is phenyl, indanyl, thienyl or furyl group which may optionally be substituted by at least one substituent selected from the group consisting of halogen, hydroxyl, nitro, amino, hydroxy-C.sub.1-4 alkyl, cyano, C.sub.1-8 alkyl, C.sub.1-4 alkoxy,C.sub.1-4 alkylthio, C.sub.1-4 alkylsulfinyl, C.sub.1-4 alkylsulfonyl, halogeno-C.sub.1-4 alkyl, di-C.sub.1-4 alkylamino, carbamoyl, or C.sub.1-4 alkanoyl, and R.sup.3 is a hydrogen or hydroxyl-protecting group selected from the group consisting of formyl, C.sub.2-5 alkanoyl, C.sub.5-8 cycloalkanecarbonyl, benzoyl, toluoyl, 2-naphthoyl, 2-thenoyl, 3-furoyl, nicotinoyl, 1,1-dimethylpropoxycarbonyl, t-butoxycarbonyl, isopropoxycarbonyl, 2,2,2-trichloroethoxycarbonyl, ethoxycarbonyl, 2,2,2-tribromoethoxycarbonyl, benzyloxycarbonyl, 4-nitrobenzyloxycarbonyl, 4-bromobenzyloxycarbonyl, 4-methoxybenzyloxycarbonyl, 3,4-dimethoxybenzyloxycarbonyl 4-(phenylazo)benzyloxycarbonyl, 4-(4-methoxyphenylazo)benzyloxycarbonyl, monochloroacetyl, trifluoroacetyl, 2-furfuryloxycarbonyl, 1adamantyloxycarbonyl, 8-quinolyloxycarbonyl, benzyl, diphenylmethyl, trityl, C.sub.1-8 alkyl, methoxymethyl, tetrahydrofuryl, tetrahydropyranyl, 2-nitrophenylthio, 2,4-dionitrophenylthio, trimethylsilyl and t-butyldimethylsilyl.
- 12. The amine compound of claim 1, wherein R.sup.4 is C.sub.1-4 alkylsulfonyl.
- 13. The amine compound of claim 12, wherein the C.sub.1-4 alkylsulfonyl is methylsulfonyl.
- 14. The amine compound of claim 11, wherein R.sup.4 l is C.sub.1-4 alkylsulfonyl.
- 15. The amine compound of claim 14, wherein the C.sub.1-4 alkylsulfonyl is methylsulfonyl.
- 16. N-(.beta.-hydroxyphenethyl)-N'-methanesulfonyl-N"-[3-(3-piperidinomethylphenoxy)propyl]guanidine or a pharmaceutically acceptable salt thereof.
- 17. An anti-ulcer composition comprising a pharmaceutically effective amount of the amine compound or a pharmaceutically acceptable salt thereof according to any one of the claims 4 and 5 to 16.
- 18. A method for treating mammals or human beings having ulcers, which comprises administering to said mammal a therapeutically effective amount of the amine compound or pharmaceutically acceptable salt thereof according to any one of claims 1 to 16.
Priority Claims (2)
Number |
Date |
Country |
Kind |
57-198434 |
Nov 1982 |
JPX |
|
58-205925 |
Nov 1983 |
JPX |
|
Parent Case Info
This application is a divisional of application Ser. No. 06/919,716 filed Oct. 16, 1986 now U.S. Pat. No. 4,923,882 which in turn is a divisional of application Ser. No. 06/550,933 filed Nov. 14, 1983, now U.S. Pat. No. 4,643,849.
US Referenced Citations (3)
Number |
Name |
Date |
Kind |
4233302 |
Martin-Smith |
Nov 1980 |
|
4304780 |
Martin-Smith |
Dec 1981 |
|
4500529 |
Shanklin et al. |
Feb 1985 |
|
Divisions (2)
|
Number |
Date |
Country |
Parent |
919716 |
Oct 1986 |
|
Parent |
550933 |
Nov 1983 |
|